HIFU appears to offer cancer control in localized PCa patients

Article

Transrectal high-intensity focused ultrasound (HIFU) appears to offer long-term cancer control in patients with low- or intermediate-risk localized prostate cancer, according to a multicenter study published in the Nov. 5, 2007, online edition of European Urology.

Transrectal high-intensity focused ultrasound (HIFU) appears to offer long-term cancer control in patients with low- or intermediate-risk localized prostate cancer, according to a multicenter study published in the Nov. 5, 2007 online edition of European Urology.

A total of 140 patients (mean age, 69 years) with T1–T2 prostate cancer, a PSA <15.0 ng/mL, and a Gleason score  ≤7 were treated with prototypes or first-generation HIFU devices (Ablatherm, EDAP TMS, Lyon, France) between October 1997 and August 2001. Mean follow-up was 6 years.

Control prostate biopsies were negative in 86.4% of patients, according to senior author Albert Gelet, MD, of Edouard Herriot Hospital in Lyon. Median PSA of 0.16 ng/mL (range, 0-9.1 ng/mL) was achieved at a mean of 4.9 months. A PSA nadir of ≤0.5 ng/mL was recorded in 68.4% of patients. The actuarial biochemical failure-free survival rates at 5 and 7 years were 77% and 69%, respectively; actuarial disease-free survival rates at 5 and 7 years were 66% and 59%, respectively.

Related Videos
Jill M. Hamilton-Reeves, PhD, RD, CSO, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Sad surgeon sitting on floor in corridor | Image Credit: © WavebreakMediaMicro - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Kevin Turner MA DM FRCS(Urol), answers a question during a Zoom video interview
© 2024 MJH Life Sciences

All rights reserved.